neo212
Diffuse Astrocytoma, IDH-Mutant
Neonc Technologies, Inc.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
8 Active assets in the Diffuse Astrocytoma, IDH-Mutant cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Safusidenib Nuvation Bio Inc. | Phase 3 | B |
Ipilimumab Neonc Technologies, Inc. | Phase 1/2 | CC |
Carboplatin Neonc Technologies, Inc. | Phase 1/2 | CC |
Regorafenib Neonc Technologies, Inc. | Phase 1/2 | CC |
Nivolumab Neonc Technologies, Inc. | Phase 1/2 | CC |
Pembrolizumab Neonc Technologies, Inc. | Phase 1/2 | CC |
Triapine National Cancer Institute (NCI) | Phase 1 | CC |
Telaglenastat National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
neo212 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →